Peripheral T-cell Lymphoma Targeted Therapy
Conditions
Brief summary
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.
Interventions
DRUGAzacitidine
Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
DRUGChidamide
Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
DRUGCyclophosphamide
Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
DRUGEpirubicin
Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
DRUGVincristine
Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
DRUGPrednisone
Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Patients must satisfy all following criteria to be enrolled in the study: 1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted. 2. Males and females of 18 years of age to 70 years of age. 3. ECOG performance status 0, 1 or 2 4. Patients with histologically proven peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH); the following subtypes as defined by the WHO classification (5th) may be included, whatever the Ann Arbor stage (I - IV): i.Angioimmunoblastic T-cell lymphoma ii. peripheral T-cell lymphoma of follicular type iii. Nodal and extra-nodal peripheral T cell lymphoma with follicular helper T cell phenotype 5. Previously received no treatment for PTCL, including chemotherapy, targeted therapy, immunotherapy, local radiotherapy for lymphoma (except for relieving tumor-related symptoms), surgical treatment (except for tumor or pathological tissue biopsy) 6. Life expectancy of ≥ 90 days (3 months) 7. At least one evaluable or measurable lesion that meets Lugano2014 criteria: lymph node lesions, which are measurable \> 1.5 cm, and non-lymph node lesions, which are measurable\>1.0 cm 8. Female and males patients of child bearing potential must use an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) during treatment period and 12 month thereafter 9. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, Platelet count ≥ 80 x 109/L, Haemoglobin ≥ 90g/L 10. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) , AST or ALT ≤ 2.5 x ULN (≤ 5 x ULN for liver involvement), serum total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for liver involvement) 11. Able to adhere to the study visit schedule and other protocol requirements.
Exclusion criteria
Presence of any of the following will exclude a patient from enrollment: 1. Previous treatment for PTCL with immunotherapy or chemotherapy except for short-term corticosteroids (duration of ≤ 8 days) before randomization 2. Contraindication to any drug contained in the chemotherapy regimen 3. Previous or current malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast have been effectively controlled) unless the patient has been free of the disease for ≥ 5 years 4. Primary or secondary central nervous system (CNS) lymphoma involvement or having a history of CNS lymphoma at the time of recruitment 5. Undergone major surgical procedures within 14 days prior to the first dose of study drug 6. Significant and uncontrolled cardiovascular disease at screening 7. Any of the following laboratory abnormalities, except if secondary to the lymphoma: 1. Absolute neutrophil count (ANC) \< 1,000 cells/mm3 (1.0 x 109/L), 2. Platelet count \< 50,000/mm3 (50 x 109/L) 3. Serum total bilirubin \> 2 x ULN, serum ALT or AST \> 3.0 x upper limit of normal (ULN), except if investigator believes that the abnormal liver function is caused by the disease 4. Serum creatinine \> 2.0 x ULN, except if investigator believes that the abnormal liver function is caused by the disease 8. Uncontrolled active systemic fungal, bacterial, viral or other infections 9. Subjects with HIV positivity 10. Subjects with active hepatitis B or C (HBs Ag+/HBc Ab+ and HBV DNA\>1x103copy/mL; HCV DNA\>1x103copy/mL) 11. Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study. 12. Other situations that investigators considered inappropriate for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | Up to 1 year |
Countries
China
Outcome results
None listed